U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C13H20N2O2.ClH
Molecular Weight 272.771
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROPROPIZINE HYDROCHLORIDE

SMILES

Cl.OCC(O)CN1CCN(CC1)C2=CC=CC=C2

InChI

InChIKey=QBZODDIRPJEEQW-UHFFFAOYSA-N
InChI=1S/C13H20N2O2.ClH/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12;/h1-5,13,16-17H,6-11H2;1H

HIDE SMILES / InChI

Molecular Formula C13H20N2O2
Molecular Weight 236.3101
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Dropropizine is a cough suppressant. It has peripheral action in non-productive cough. Dropropizine is commercialized in Latin American and African countries.

CNS Activity

Originator

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TROFERIT

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
30 mg 6 or 8 hourly
Route of Administration: Oral
In Vitro Use Guide
When the Chinese hamster V79 cells were treated with the highest concentration of Dropropizine (8000 ug/ml), cytostatic effects lasting 24 h were observed
Substance Class Chemical
Record UNII
30H39EX30A
Record Status Validated (UNII)
Record Version